AstraZeneca

AstraZeneca's Tagrisso, chemo combination shows promise in lung cancer trial
Yahoo/Reuters
Wed, 05/17/23 - 11:16 am
AstraZeneca
clinical trials
Tagrisso
AstraZeneca is third member to leave PhRMA in five months
Stat
Tue, 05/16/23 - 12:03 pm
AstraZeneca
lobbying
PhRMA
AstraZeneca Expands ADC Portfolio with $600M Deal with LaNova
BioSpace
Mon, 05/15/23 - 06:35 pm
AstraZeneca
antibody-drug conjugate
LaNova Medicines
The waxing and waning of the speedy approval
EP Vantage
Mon, 05/15/23 - 09:58 am
FDA
drug approvals
accelerated approvals
AbbVie
AstraZeneca
Bayer
Bristol Myers Squibb
JNJ
Merck
Merck KGaA
Novartis
Pfizer
Farxiga’s approval for expanded use highlights potential to differentiate in HF space
Clinical Trials Arena
Fri, 05/12/23 - 11:42 am
AstraZeneca
Farxiga
heart failure
2023’s biggest launches: the story so far
EP Vantage
Fri, 05/12/23 - 10:19 am
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Sanofi, AstraZeneca Report Promising RSV Pediatric Data Ahead of Pfizer Adcomm
BioSpace
Fri, 05/12/23 - 10:16 am
Sanofi
AstraZeneca
RSV
antibodies
infants
clinical trials
A blockbuster year could be building
EP Vantage
Wed, 05/10/23 - 09:55 am
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Farxiga Approval Expands Use to More Patients With Heart Failure
eMPR
Tue, 05/9/23 - 11:28 pm
AstraZeneca
Farxiga
FDA
Biopharma Bets Big on Antibody-Drug Conjugates
BioSpace
Mon, 05/8/23 - 10:20 am
antibody-drug conjugate
Merck
Seagen
M&A
AstraZeneca
BioNTech
Bristol Myers Squibb
AstraZeneca, Pfizer Top 2023 Pharma List for Invention and Innovation
BioSpace
Sun, 05/7/23 - 10:23 pm
reputation
AstraZeneca
Pfizer
innovation
IDEA Pharma
AstraZeneca scraps pact with Riva-led Transgene in further blow to oncolytic viruses
Fierce Biotech
Fri, 05/5/23 - 10:18 am
AstraZeneca
oncolytic viruses
Transgene
Bristol Myers accuses AstraZeneca of infringing patent on cancer blockbuster Opdivo—again
Fierce Pharma
Tue, 05/2/23 - 11:30 pm
Bristol Myers Squibb
Opdivo
patents
legal
AstraZeneca
With negative FDA panel vote, AstraZeneca's Lynparza looks set for narrow nod in prostate cancer
Fierce Pharma
Mon, 05/1/23 - 10:16 am
AstraZeneca
Merck
Lynparza
metastatic castration-resistant prostate cancer
FDA Questions Efficacy of Merck-AstraZeneca’s Lynparza Ahead of Adcomm
BioSpace
Thu, 04/27/23 - 10:58 pm
Merck
AstraZeneca
FDA
Lynparza
metastatic castration-resistant prostate cancer
AstraZeneca dumps $855M, near-approval rare disease drug after talks with regulators
Fierce Biotech
Thu, 04/27/23 - 10:34 am
AstraZeneca
clinical trials
ALXN1840
Wilson disease
AstraZeneca overtakes Pfizer as crunch week for UK pharma looms
The Guardian, UK
Tue, 04/25/23 - 10:15 pm
AstraZeneca
Pfizer
earnings
Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam
Fierce Biotech
Mon, 04/24/23 - 10:26 am
Ionis Pharmaceuticals
AstraZeneca
eplontersen
Alnylam
ATTR
Drugmakers take sides in Amgen, Regeneron fight over antibody patents
BioPharma Dive
Mon, 04/24/23 - 10:17 am
Amgen
Regeneron Pharmaceuticals
Sanofi
Supreme Court
patents
Pfizer
Bayer
Roche
Genentech
AstraZeneca
JNJ
Big pharma holds steady on research spending
EP Vantage
Fri, 04/21/23 - 10:03 am
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals

Pages